<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04402281</url>
  </required_header>
  <id_info>
    <org_study_id>§33, HUS/141/2020 14.4.2020</org_study_id>
    <nct_id>NCT04402281</nct_id>
  </id_info>
  <brief_title>Use of suPAR Algorithm for the ED Decision Making</brief_title>
  <acronym>EDsuPAR</acronym>
  <official_title>Use of Algorithm for Safer and More Efficient Decision Making in the ED</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Will the use of a clinical decision algorithm in the ED improve discharge or admission
      decisions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Crowding and readmissions are common challenges in Emergency departments across
      Europe. The decision whether to admit or discharge the patient is challenging and is often
      based on clinical signs and symptoms e.g. blood pressure, pulse, respiratory rate, oxygen
      saturation and temperature. But some patients are unnecessarily admitted and may have been
      better off if sent home. Other patients may be discharged without - and one out of five
      patients are readmitted within a month raising the question whether the patient should have
      been admitted at first presentation in the ED. suPAR is a strong prognostic biomarker
      measured routinely in acute medical patients in some emergency department (ED) settings.suPAR
      is a broadly applicable biomarker of risk, and it has been developed an algorithm for simple
      interpretation of suPAR in clinical decisions for the study.

      Objective To evaluate the use of a clinical decision algorithm in the ED with the aim of
      improving discharge or admission decisions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Interventional study.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Discharges</measure>
    <time_frame>30 days</time_frame>
    <description>Number of discharges from the ED within 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Admissions</measure>
    <time_frame>30 days</time_frame>
    <description>Number of admissions to hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>30 days</time_frame>
    <description>Length of stay during admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmissions</measure>
    <time_frame>1,7 and 30 days</time_frame>
    <description>Number of readmissions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Number of Mortality</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Economical savings</measure>
    <time_frame>30 days</time_frame>
    <description>Amount of money</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>suPAR algoritm control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control arm (Meilahti hospital): Samples are collected and suPAR measured but no algorithm is implemented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>suPAR algoritm intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention arm (Jorvi Hospital).
According the algorithm when admitting a patient with suPAR below 3 ng/ml, physician should answer the following question
&quot;Are you sure it is the right decision to admit this patient? Please discuss this with a senior physician&quot;.
If discharging a patient with suPAR above 6 ng/ml, physician should answer the following question
&quot;Are you sure it is the right decision to discharge this patient? Please discuss this with a senior physician&quot;.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>suPAR algoritm</intervention_name>
    <description>All medical patients attending to the ED and who will have blood drawn for routine examination will be part of the study. In patients with low suPAR (green group, suPAR below 3 ng/ml) and in patients with high suPAR (red group, suPAR &gt; 6 ng/mL) the Intervention will be carried out</description>
    <arm_group_label>suPAR algoritm control</arm_group_label>
    <arm_group_label>suPAR algoritm intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients above 18 years

          -  who are having blood taken for biochemical analysis when attending the ED

        Exclusion Criteria:

          -  Acute medical patients that do not have blood drawn for routine biochemical testing.

          -  Pregnant

          -  Under 18 years old

          -  Terminally ill patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>104 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maaret Castrén, Docent</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marja Mäkinen, PhD</last_name>
    <phone>+3587754585</phone>
    <email>marja.makinen@hus.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maaret Castrén, Docent</last_name>
    <email>maaret.castren@hus.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Emergency Medicine and Services, Helsinki University Hospital and Helsinki University, Helsinki, Finland</name>
      <address>
        <city>Helsinki</city>
        <state>Helsinki Usimaa</state>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marja Mäkinen, PhD</last_name>
      <phone>+358407754585</phone>
      <email>marja.makinen@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Maaret Castrén, MD, PhD, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timo Suonsyrjä, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johanna Kaartinen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marja Mäkinen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 20, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>July 11, 2020</last_update_submitted>
  <last_update_submitted_qc>July 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Marja Mäkinen</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>ED</keyword>
  <keyword>Critical illness</keyword>
  <keyword>Decision making</keyword>
  <keyword>POC test</keyword>
  <keyword>suPAR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

